Department of Ophthalmology "Iuliu Haţieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Medical Doctoral School, University of Oradea, Oradea, Romania.
Arq Bras Oftalmol. 2023 Mar-Apr;86(2):105-112. doi: 10.5935/0004-2749.20230037.
We aimed to evaluate the factors influencing the visual gain following pars plana vitrectomy for vitreous hemorrhage in patients with proliferative diabetic retinopathy.
A retrospective study was conducted on 172 eyes of 143 consecutive patients with diabetes mellitus between January 2012 and January 2018. Demographic data, ophthalmological findings, surgery details, and visual outcomes were gathered after consulting the patients' records. The main outcome measured was the improvement of best corrected visual acuity and the secondary outcomes measured were rebleeding and complications.
Best corrected visual acuity improved in 103 eyes (59.88%), worsened in 45 eyes (26.16%), and remained unchanged in 24 eyes (13.95%). Type 2 diabetes mellitus was significantly associated with better final best corrected visual acuity (p=0.0244). Previous treatment by pan-retinal laser photocoagulation or intravitreal bevacizumab determined better final best corrected visual acuity, but not significantly (p>0.05). Preoperative rubeosis iridis and neovascular glaucoma did not influence the outcomes. The lack of fibrovascular proliferation requiring dissection was a significant factor for better final best corrected visual acuity (p=0.0006). Rebleeding occurred in 37.1% of the eyes and it was not influenced by the antiplatelet drugs (p>0.05). Postoperative neovascular glaucoma was a negative prognostic factor (p=0.0037).
The final best corrected visual acuity was influenced positively by type 2 diabetes mellitus and the absence of preoperative extensive fibrovascular proliferation and negatively by postoperative neovascular glaucoma.
评估增生型糖尿病视网膜病变患者玻璃体积血行玻璃体切割术后视力提高的影响因素。
对 2012 年 1 月至 2018 年 1 月期间的 143 例连续糖尿病患者的 172 只眼进行回顾性研究。通过查阅患者病历,收集人口统计学资料、眼科检查结果、手术细节和视力结果。主要观察指标为最佳矫正视力的改善情况,次要观察指标为再出血和并发症。
103 只眼(59.88%)视力提高,45 只眼(26.16%)视力恶化,24 只眼(13.95%)视力不变。2 型糖尿病与最终最佳矫正视力较好显著相关(p=0.0244)。全视网膜激光光凝或玻璃体腔内贝伐单抗治疗史与最终最佳矫正视力较好相关,但无统计学意义(p>0.05)。术前虹膜新生血管和新生血管性青光眼不影响结果。需要分离的无纤维血管性增殖是最终最佳矫正视力较好的显著因素(p=0.0006)。37.1%的眼发生再出血,抗血小板药物不影响再出血(p>0.05)。术后新生血管性青光眼是一个负性预后因素(p=0.0037)。
最终最佳矫正视力受 2 型糖尿病和术前无广泛纤维血管增殖的积极影响,受术后新生血管性青光眼的消极影响。